EMD Serono begins MSB0010718C Phase II study in mMCC patients

[News]

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).

More... (http://www.news-medical.net/news/20140729/EMD-Serono-begins-MSB0010718C-Phase-II-study-in-mMCC-patients.aspx)